Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q1 FY2017 Earnings Presentation
16 slides from Dr. Lal Pathlabs's earnings presentation, Jul 29, 2016
Slide 1: Dr. Lal PathLabs Limited (LPL) Q1 FY17 Results Presentation
Dr. Lal PathLabs Limited (LPL) Q1 FY17 Results Presentation July 29, 2016
Slide 2: Table of Contents
Table of Contents 1 Overview of Dr. Lal PathLabs 2 Key Highlights 3 Q1 FY2017 Financial Performance 4 Financial Highlights 5 Operating Highlights 6 Management Commentary 7 Outlook 8 Corporate Overview 9 Contact Us DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The
Slide 3: Overview of Dr Lal PathLabs
Overview of Dr Lal PathLabs 172 clinical labs (including Established consumer National Reference Lab at healthcare brand in Delhi),1,559 Patient Service diagnostic services Centers (PSCs) and 4,967 Pick-up Points (PUPs)* Scalable model integrated Catalogue of 1,110 test through centralized IT panels
Slide 4: Key Highlights
Key Highlights Aiming for sustainable robust growth backed by healthy fundamentals Strategy in action; network expansion driving incremental performance During Q1 FY17 LPL reported: Revenues grew 17.7% at Rs. 2,228.4 mn from Rs. 1,893.1 mn EBITDA stood increased 22.7% to Rs. 604.0 mn from
Slide 5: Q1 FY17 Financial Performance
Q1 FY17 Financial Performance Particulars (Rs. mn) Q1 FY17 Q1 FY16 Growth % Revenues 2,228.4 1,893.1 17.7% Total Expenditure 1,624.3 1,378.5 17.8% ESOP - 22.5 - EBITDA 604.0 492.1 22.7% Margins 27.1% 26.0% 110 bps PBT 599.3 468.3 28.0% Margins 26.9% 24.7% 220 bps PAT 401.7 309.8 29.7% Margins 18.0%
Slide 6: Financial Highlights: Revenues
Financial Highlights All figures in Rs mn Revenues Q1 FY17 revenues improved 17.7% YoY on the back of 15% increment in volumes and improvement in 2,228 realisations Realisation per patient has enhanced to Rs. 678, up 2.4% from Rs. 662 in Q1 FY16 Volume growth of 15% driven by; Increase in pa
Slide 7: Financial Highlights: EBITDA
Financial Highlights All figures in Rs mn EBITDA EBITDA showed 22.7% gains during Q1 FY17 with EBITDA Margins at 27.1% for Q1 FY17 Normalised EBITDA growth 17.3% after excluding 604 impact of ESOP charge in Q1FY16 492 Factors impacting EBITDA during the period include; Growth in topline on t
Slide 8: Financial Highlights: PAT
Financial Highlights All figures in Rs mn PAT PBT growth during Q1 FY17 was at 28.0% Margins stood at 26.9% in the period PAT showed 29.7% increase in Q1 FY17 402 Results reflect strategic progress realised against opportunity presented by the healthcare sector 310 Q1FY16 Q1FY17 8
Slide 9: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 1,559 172 5,668 164 1,340 4,967 4,225 1,064 146 824 2,879 131 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 No. of patients (mn) No. of samples (mn) 26.3 12.0 21.7 19.0 9.9 16.0 9.0 7.7 FY13 FY14 FY15 FY16 FY13 F
Slide 10: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal - Chairman and Managing Director said; “I am pleased to announce that the Company’s concerted efforts, further advanced our scorecard allowing us to finish this quarter with healthy results. These stand reflective of the un
Slide 11: Outlook
Outlook Robust operating model best-positioned to capitalize on growth trends in diagnostic services -one of the fastest-growing segments of the Indian healthcare industry Will leverage established position of a strong consumer healthcare brand in diagnostic services . Initiatives to improve brand c
Slide 12: Corporate Overview
Corporate Overview • LPL Strategy for future growth • Experienced Management team 12
Slide 13: LPL Strategy for future growth
LPL Strategy for future growth 1) Strengthen Existing 2) Expansion in Offering Operations 3) Expand management of hospital based and clinical 4) Geographic expansion laboratories 13
Slide 14: LPL Strategy for future growth
LPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & Life
Slide 15: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Manoj Garg Shankha Banerjee Chief Financial Officer Chief Human Resources Officer COO – Strategic
Slide 16: Contact us
Contact us About Dr Lal PathLabs Limited (LPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and